Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Taysha Gene Therapies, Inc. publishes a filing, an earnings call transcript or a press release.

Get TSHA alerts

About Kamran Alam

Kamran Alam is recorded as CFO at Taysha Gene Therapies, Inc. (TSHA). The newest filing on record that lists Kamran Alam as CFO at Taysha Gene Therapies, Inc. (TSHA) is dated April 22, 2026. The proxy statement of Taysha Gene Therapies, Inc. reports total compensation of $2,146,964 for Kamran Alam in fiscal 2025, including a base salary of $473,331. Disclosed compensation is on record for 6 fiscal years. Kamran Alam has spoken on 17 earnings calls across 1 company, most recently for Taysha Gene Therapies, Inc. on May 15, 2025. Taysha Gene Therapies, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Taysha Gene Therapies, Inc. includes Sean Nolan (CEO and Board Member), Laura Sepp-Lorenzino (Board Member), Sean Stalfort (Board Member) and 1 other.

Kamran Alam on recent calls

“Research and development expenses were $15.6 million for the three months ended March 31, 2025 compared to $20.7 million for the three months ended March 31, 2024.”
CFO, Taysha Gene Therapies, Inc. Q1 FY2025 Earnings Call ·
“Research and development expenses were $66.0 million for the full year ended December 31, 2024, compared to $56.8 million for the full year ended December 31, 2023.”
CFO, Taysha Gene Therapies, Inc. Q4 FY2024 Earnings Call ·
“Research and development expenses were $14.9 million for the three months ended September 30, 2024, compared to $11.8 million for the three months ended September 30, 2023.”
CFO, Taysha Gene Therapies, Inc. Q3 FY2024 Earnings Call ·
“Research and development expenses were $15.1 million for the three months ended June 30, 2024 compared to $19.8 million for the three months ending June 30, 2023.”
CFO, Taysha Gene Therapies, Inc. Q2 FY2024 Earnings Call ·
“Research and development expenses were $20.7 million for the 3 months ended March 31, 2024, compared to $12.5 million for the 3 months ending March 31, 2023.”
CFO, Taysha Gene Therapies, Inc. Q1 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Taysha Gene Therapies, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Taysha Gene Therapies, Inc. (TSHA) $473,331 $2,146,964
2024 Taysha Gene Therapies, Inc. (TSHA) $455,126 $2,518,777
2023 Taysha Gene Therapies, Inc. (TSHA) $413,751 $975,401
2022 Taysha Gene Therapies, Inc. (TSHA) $401,700 $1,201,823
2020 Rocket Pharmaceuticals, Inc. (RCKT) $197,230 $634,250
2019 Rocket Pharmaceuticals, Inc. (RCKT) $54,545 $2,051,457

Recent activity

Show 5 earlier activities